Janis Taube

Oncology · 2010–2023

A researcher in the Science corpus: 15 papers; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 254 citations into it; #1,282 of 1,698 by trust here, #53 by citations
• Immunology — 188 citations into it; #1,632 of 2,160 by trust here, #235 by citations

Whom Janis Taube trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Topalian
2. Taku Okazaki

Who trusts Janis Taube overall

1. Lieping Chen
2. S. Topalian
3. M. Teng
4. W. Zou
5. S. Ngiow
6. Antoni Ribas
7. Xue Han
8. J. Wolchok
9. S. Patel

Papers from Janis Taube's perspective

Ordered by how strongly the researchers Janis Taube trusts endorse each paper. Same corpus, a different order for every researcher.

1. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
2. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
5. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (Cancer Research)
6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
7. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
8. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
9. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
10. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)

Their papers

• Fulminant Myocarditis with Combination Immune Checkpoint Blockade (2016) — 1,956 citations
• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) — 1,526 citations
• Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (2022) — 2,035 citations
• Neoadjuvant checkpoint blockade for cancer immunotherapy (2020) — 879 citations
• Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (2018) — 1,781 citations
• A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry (2017) — 718 citations
• Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade (2017) — 5,893 citations
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) — 1,115 citations
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016) — 2,482 citations
• Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016) — 703 citations
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015) — 4,624 citations
• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014) — 2,243 citations
• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013) — 738 citations
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) — 2,143 citations
• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) — 2,866 citations